Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating

Published on 2025-03-11 at 11:11 - Modified on 2025-03-11 at 11:23

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. - Special Call	07-07
Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target	06-17	MT
Protagonist Therapeutics, Inc. - Special Call	06-16
Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide	06-02	CI
Protagonist Therapeutics, Takeda's Potential Polycythemia Vera Drug Meets Primary Endpoint	06-02	MT
Takeda Presents Clinical Data of Polycythemia Vera Treatment at Oncology Conference	06-02	MT
J&J's oral psoriasis drug helps patients achieve clear skin in late-stage study	05-09	RE
Johnson & Johnson, Protagonist Therapeutics Say Psoriasis Drug Cleared Skin in Late-Stage Study	05-09	MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-06	CI
Protagonist Therapeutics Takeda To Lead Regulatory Strategy For Rusfertide In Polycythemia Vera NDA	03-20	RE
Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating	03-11	MT
Sector Update: Health Care Stocks Decline Late Afternoon	03-10	MT
Top Midday Gainers	03-10	MT
Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra	03-10	DJ
Truist Securities Adjusts Price Target on Protagonist Therapeutics to $76 From $60, Keeps Buy Rating	03-10	MT
Protagonist, Johnson & Johnson Say Phase 2b Icotrokinra Study Meets Primary Endpoint in Ulcerative Colitis	03-10	MT
Protagonist Therapeutics, Inc. Announces New Icotrokinra (Jnj-2113) Data from the Comprehensive Phase 3 Clinical Program and the Planned Initiation of the First-Ever Head-To-Head Study in Plaque Psoriasis	03-10	CI
Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera	03-03	MT
Protagonist Therapeutics, Inc. - Special Call	03-03
Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide	03-03	RE
Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Announces Positive Topline Results from Phase 3 Verify Study of Rusfertide in Patients with Polycythemia Vera	03-03	CI
Protagonist Therapeutics' Q4 Earnings, License and Collaboration Revenue Rise	02-21	MT
Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 License, Collaboration Revenue $170.6M	02-21	MT
Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 EPS $1.98	02-21	MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	02-21	CI

PROTAGONIST THERAPEUTICS, INC.

Stock

PTGX

US74366E1029

Market Closed - Nasdaq Other stock markets 16:00:00 2025-07-18 EDT
55.48 ^USD	-1.70%

More quotes

Chart

Duration

Period

PTGX: Dynamic Chart

Income Statement and Estimates

More financial data

Headlines

Weekly market update: Earnings Wave Ahead

Ashish Kacholia and Dolly Khanna: India's Star Investors Send Portfolio Signals

July 18, 2025 at 05:13 am

Employment figures offer some respite for the Bank of England

July 17, 2025 at 10:25 am

Results preview: Legrand accelerates

July 17, 2025 at 05:51 am

Crypto companies face the fatal trap of Bitcoin - Crypto roundup

July 17, 2025 at 05:24 am

When volatility boosts US banks

July 17, 2025 at 04:42 am

Shorting the dollar: the most popular trade amongst fund managers

July 17, 2025 at 03:20 am

The Week's Biggest Mergers Unpacked

July 16, 2025 at 10:12 am

Diageo reshuffles its management team: Nik Jhangiani temporarily replaces Debra Crew

July 16, 2025 at 09:29 am

How did Indonesia go from 32% to 19% customs tariffs?

July 16, 2025 at 09:23 am

All our articles